Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)

Round 1

Reviewer 1 Report

Nicely written case report of late-onset EBV negative PTCL-NOS PTLD after liver transplant in a while male with cryptogenic cirrhosis. The authors could improve the manuscript by incorporating the deauville 5-point scale and Lugano response criteria into their manuscript. Also the authors should acknowledge that reduced immunosuppression and the two cycles of CHOP received also contributed to the positive outcome in their patient. 

Author Response

As suggested by the reviewer we included Deauville score and acknowledged the contribution of reducing immunosuppresion and 2 cycles of CHOP. Thank you. 

Reviewer 2 Report

Jennifer Hong et al. presented a patient with T cell PTLD after liver transplantation. The authors presented the case clearly and provided the essential information. Overall, this is a well-written case report.

Author Response

Thank you. We appreciate your time and effort to providing feedback. 

Reviewer 3 Report

The authors have submitted a report detailing a case of T cell monomorphic PTLD treated with brentuximab vedotin plus chemotherapy. This is the report using this drug in a patient with PTLD, so it does have significance, however being a case report the significance is limited. The report is overall very well written but probably too long for a case report. Table 1 does not add to the manuscript and should be deleted (subtypes of PTLD have been described in many papers). The conclusion paragraph is too long and should be only a few lines. The discussion is too long and some information in the introduction is repeated. 

Author Response

As suggested by the reviewer we have removed Table 1 and shortened the conclusion paragraph and discussion. Thank you.